Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Citius Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CTXR
Nasdaq
8731
https://www.citiuspharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Citius Pharmaceuticals Inc
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
- Apr 11th, 2024 12:30 pm
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
- Apr 4th, 2024 12:30 pm
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Mar 18th, 2024 12:30 pm
Sidoti Events, LLC's Virtual March Small-Cap Conference
- Mar 12th, 2024 2:30 pm
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
- Mar 7th, 2024 1:30 pm
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
- Feb 26th, 2024 12:30 pm
Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
- Feb 23rd, 2024 1:30 pm
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
- Feb 14th, 2024 9:30 pm
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Feb 14th, 2024 1:01 pm
Breakeven On The Horizon For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
- Feb 11th, 2024 1:10 pm
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
- Jan 23rd, 2024 1:30 pm
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
- Jan 2nd, 2024 1:31 pm
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
- Jan 2nd, 2024 1:30 pm
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
- Dec 3rd, 2023 2:24 pm
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
- Nov 14th, 2023 1:55 pm
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
- Nov 9th, 2023 1:30 pm
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
- Oct 31st, 2023 12:45 pm
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
- Oct 24th, 2023 11:30 am
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
- Sep 21st, 2023 1:35 pm
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
- Sep 18th, 2023 8:30 pm
Scroll